ENLV

Enlivex Therapeutics Ltd

ENLV, USA

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.

https://www.enlivex.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ENLV
stock
ENLV

Enlivex: A Necessary Update - This Is No Longer The Company We Covered In 2022 (NASDAQ:ENLV) Seeking Alpha

Read more →
ENLV
stock
ENLV

Enlivex Therapeutics Ltd. (ENLV) Stock Price | Live Quotes & Charts | NASDAQ StocksToTrade

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$7

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.28

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-12.61 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.53 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.20

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 10.77% of the total shares of Enlivex Therapeutics Ltd

1.

Armistice Capital, LLC

(5.9258%)

since

2025/06/30

2.

Millennium Management LLC

(2.5669%)

since

2025/06/30

3.

Morgan Stanley - Brokerage Accounts

(0.9189%)

since

2025/06/30

4.

Renaissance Technologies Corp

(0.706%)

since

2025/06/30

5.

Jane Street Group LLC

(0.256%)

since

2025/06/30

6.

Sigma Investment Counselors Inc

(0.1174%)

since

2025/06/30

7.

Neuberger Berman Group LLC

(0.0461%)

since

2025/06/30

8.

SkyView Investment Advisors, LLC

(0.0419%)

since

2025/06/30

9.

Wells Fargo & Co

(0.0385%)

since

2025/06/30

10.

Advisor Group Holdings, Inc.

(0.0299%)

since

2025/06/30

11.

Group One Trading, LP

(0.0294%)

since

2025/06/30

12.

Fidelity Nasdaq Composite Index

(0.0238%)

since

2025/07/31

13.

SignatureFD, LLC

(0.021%)

since

2025/06/30

14.

Bank of America Corp

(0.0128%)

since

2025/06/30

15.

Steward Partners Investment Advisory, LLC

(0.0105%)

since

2025/06/30

16.

JPMorgan Chase & Co

(0.0076%)

since

2025/06/30

17.

SRS Capital Advisors Inc

(0.0043%)

since

2025/06/30

18.

Bfsg, LLC

(0.0042%)

since

2025/06/30

19.

Activest Wealth Management

(0.0042%)

since

2025/06/30

20.

Spire Wealth Management

(0.0021%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1426

Latest Release

Date

2025-09-30

EPS Actual

-0.09

EPS Estimate

-0.144

EPS Difference

0.054

Surprise Percent

37.5%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.